GeSiM
Develops modular 3D bioprinters and liquid handling instruments for tissue engineering and biofabrication, enabling precise deposition of bioinks, cells, and biopolymers.
- CEO / Founder
- Dr. Frank F. Bier
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- Undisclosed
- Latest Round
- Series C
Technology & Products
Key Products
3D bioprinters (e.g., BioScaffolder series); Microarray printers (Nano-Plotter); Microcontact printers; Chemical synthesizers; Microfluidic workstations
Technological Advantage
Proprietary liquid handling technology achieves 100-micron spot resolution for microarrays and multi-material bioprinting, protected by trade secrets and decades of micromachining experience.
Differentiation
Value Proposition
Provides high-precision, modular bioprinting systems that reduce experimental setup time by 50% and enable multi-material printing for complex tissue scaffolds, accelerating research and development in life sciences.
How They Differentiate
Offers modular, high-precision bioprinters with XYZ accuracy down to 1 micron vs. competitors' 10-50 micron, and integrates microarray printing and microfluidics in one platform, unlike single-function bioprinters.
Market & Competition
Target Customers
Research institutions, biotech companies, and diagnostic firms in tissue engineering, regenerative medicine, and drug discovery.
Industry Verticals
Biotechnology; Medical Research; Diagnostics; Pharmaceuticals
Competitors
EnvisionTEC (now Desktop Metal); Organovo; CELLINK (now BICO)
Growth & Milestones
Growth Metrics
Listed as a key player in the 3D bioprinting market among competitors like Organovo, Cellink, and Stratasys; operates in a market segmented by type and application with growth projections from 2024-2032
Major Milestones
Founded in 1995 as spin-off from Rossendorf Research Center; Development of BS3.3 Prime and BS5.x bioprinter series; Partnership with InnoRegen for bioink distribution; Featured in academic publications and conferences like Additive Manufacturing Meets Medicine
Notable Customers
Sunlant bioengineering Co., Ltd.; Fraunhofer ISIT; University of Michigan, Ann Arbor; University of Clermont, France; University of Otago, New Zealand; Friedrich-Alexander University Erlangen (FAU); Technical University Dresden; Fraunhofer IWS Dresden